by Richard Lafayette, MD, FACP; Carla M. Nester, MD, MSA, FASN; and Jai Radhakrishnan, MD, MS
There is hope that advancements in the science of complement inhibition will allow clinicians to do more for their patients with complement-driven ......READ MORE
The proximal portion of the alternative complement activation pathway plays an important role in the pathogenesis of immunoglobulin A nephropathy (......READ MORE
Patients with immunoglobulin A nephropathy (IgAN) and complement 3 glomerulopathy (C3G) have a variable risk of disease progression. Considerable p......READ MORE
by Richard Lafayette, MD, FACP; Carla M. Nester, MD, MSA, FASN; and Jai Radhakrishnan, MD, MS
Current management recommendations for immunoglobulin A nephropathy (IgAN) focus on optimizing supportive treatments to help slow the progression t......READ MORE
by Richard Lafayette, MD, FACP; Carla M. Nester, MD, MSA, FASN; and Jai Radhakrishnan, MD, MS
There may be a rationale for studying complement-targeting strategies in etiologically distinct glomerular diseases such as complement 3 glomerulop......READ MORE
Complement 3 glomerulopathy (C3G) shares many clinicopathologic features with infection-related glomerulonephritis (IRGN), including acute nephriti......READ MORE
